Concord Biotech Ltd
Concord Biotech | 543960
Stock Performance
Ratios
About Company
- Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies
- Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC
- The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India
- Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products
- Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat
- In 2000, the Company was acquired by the Promoter, Mr
- In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States
- It established a facility at Valthera, Gujarat
- It set up a joint venture in Japan to grow business in 2018
- In 2019, the Company received two ANDA approvals
Technical Indicators
Pivot Points
Volume Analysis
Growth Rate
All figures in ₹ Crores
No Information Available
No shareholding data available at this time.
No Data Available
No Block Deals data available for this company.
News
Peers
#IndiaInvests
Trusted by 2.5 lac + Indians for their wealth-building needs
Invest in stocks with ease
Open your account in less than 10 mins*
By proceeding, you agree to all T&C *
Frequently Asked Questions
What is Share Price of Concord Biotech Ltd?
The current share price of Concord Biotech Ltd (Concord Biotech) is ₹1502.30. This price reflects the latest market valuation and is updated in real-time during trading hours.
What is the P/E Ratio of Concord Biotech Ltd?
The Price-to-Earnings (P/E) ratio of Concord Biotech Ltd is 1502.30. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.
What is the 52-week high and low of Concord Biotech Ltd?
Concord Biotech Ltd has a 52-week high of ₹2451.70 and a 52-week low of ₹1345.00. This range shows the stock's price volatility over the past year.
What is the Dividend Yield of Concord Biotech Ltd?
Concord Biotech Ltd offers a dividend yield of 0.58%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.
What is the EPS of Concord Biotech Ltd?
The Earnings Per Share (EPS) of Concord Biotech Ltd is ₹34.04. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.
What is the ROE of Concord Biotech Ltd?
Concord Biotech Ltd has a Return on Equity (ROE) of 22.35%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.
Disclaimer:
Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.
